Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone for Metabolic Abnormalities in Schizophrenia
NCT00231894Phase 4Completed
- Sponsor
- Nathan S. Kline Institute for Psychiatric Research
- Start
- May 2005
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hyperglycemia, dyslipidemia and insulin resistance (IR) comparing Pioglitazone + Lifestyle with Placebo + Lifestyle (2 arms). Primary endpoints: Change From Baseline in Serum Triglycerides at 3 months, Change From Baseline in Serum HDL at 3 months and 2 more. Started May 2005; status: completed.
02
Drugs
pioglitazone
03
Conditions
hyperglycemiadyslipidemiainsulin resistance (IR)
Beyond the preview
Go deeper on NCT00231894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00231894.